CSL posts strong sales and profit growth
By Roger Montgomery
Australian Securities Exchange (ASX) healthcare leader CSL (ASX:CSL) posted a robust 11 per cent rise in sales from US$13. 3 billion to US$14. 8 billion, with CSL’s Behring segment, that markets products like immunoglobulin derived from blood plasma, contributing over 70 per cent of total sales. The company also reported a 21.